MCID: CRV031
MIFTS: 49

Cervical Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 58 54 15 17 71
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of the Cervix Uteri 58
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3702
NCIt 49 C4029
SNOMED-CT 67 254887002
ICD10 via Orphanet 33 C53.0 C53.1 C53.8
UMLS via Orphanet 72 C0279672
Orphanet 58 ORPHA213772
UMLS 71 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to wolffian duct adenocarcinoma and suppressor of tumorigenicity 3. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Gastric cancer and MicroRNAs in cancer. The drugs Epoetin alfa and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are cellular and cardiovascular system

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)
# Related Disease Score Top Affiliating Genes
1 wolffian duct adenocarcinoma 32.5 TP53 KRT7 ESR1 CALB2
2 suppressor of tumorigenicity 3 31.5 TP53 CDKN2A CDKN1A
3 adenocarcinoma in situ 31.4 KRT7 KRT20 EGFR CEACAM5 CDX2 CDKN2A
4 adenocarcinoma 31.3 TP53 PTEN KRT7 KRT20 EGFR CEACAM5
5 myoma 31.2 TP53 ESR1 EGFR
6 clear cell adenocarcinoma 31.1 TP53 KRT7 KRT20
7 cervical squamous cell carcinoma 31.0 TP53 RASSF1 LRIG3 EGFR CDKN2A
8 papillary serous adenocarcinoma 31.0 TP53 KRT7 KRT20 CEACAM5 CALB2
9 adenosquamous carcinoma 30.9 TP53 PTEN KRT7 EGFR CEACAM7 CEACAM5
10 appendix adenocarcinoma 30.9 KRT7 KRT20 CEACAM5 CDX2
11 squamous cell papilloma 30.9 TP53 CDKN2A
12 papillary transitional carcinoma 30.9 TP53 KRT7 KRT20
13 signet ring cell adenocarcinoma 30.8 TP53 KRT7 KRT20 CEACAM5 CDX2
14 bilateral breast cancer 30.7 PTEN ESR1 CDKN2A
15 breast fibroadenoma 30.7 TP53 RASSF1 ESR1
16 mucinous cystadenocarcinoma 30.7 KRT7 KRT20 CEACAM7 CEACAM5
17 hepatoid adenocarcinoma 30.7 KRT7 EGFR CEACAM5 CDX2
18 in situ carcinoma 30.7 TP53 PTEN ESR1 EGFR CDKN2A
19 vulval paget's disease 30.7 KRT7 CEACAM5
20 ovarian brenner tumor 30.6 KRT7 KRT20
21 cystadenocarcinoma 30.6 TP53 KRT7 CEACAM5 CDKN1A
22 serous cystadenocarcinoma 30.6 TP53 PTEN KRT7 CDKN2A CDKN1A
23 endocervical adenocarcinoma 30.5 TP53 KRT7 KRT20 ESR1 CEACAM5 CDX2
24 cervix carcinoma 30.5 TP53 MIR362 CEACAM5 CDKN2A
25 squamous cell carcinoma 30.5 TP53 PTEN KRT7 EGFR CEACAM5 CDKN2A
26 mammary paget's disease 30.5 KRT7 KRT20 ESR1 EGFR
27 peutz-jeghers syndrome 30.4 TP53 PTEN EGFR
28 adenomyoma 30.4 KRT7 ESR1 CDKN2A
29 cystitis 30.3 TP53 KRT7 KRT20 CDX2
30 ovarian serous carcinoma 30.3 TP53 CDKN2A CALB2
31 ovarian cystadenocarcinoma 30.3 TP53 PTEN EGFR CEACAM5 CDKN2A CALB2
32 intestinal obstruction 30.2 KRT7 KRT20 CEACAM5 CDX2
33 papillary adenocarcinoma 30.2 TP53 KRT7 CEACAM5 CDX2
34 mucinous adenocarcinoma 30.2 TP53 KRT7 KRT20 ESR1 EGFR CEACAM5
35 adenoma 30.2 TP53 KRT7 KRT20 CDX2 CDKN2A
36 endometriosis 30.2 TP53 PTEN ESR1 CALB2
37 small cell carcinoma 30.2 TP53 PTEN KRT7 KRT20 EGFR CDX2
38 transitional cell carcinoma 30.2 TP53 PTEN KRT7 KRT20 EGFR CDKN2A
39 endocervical carcinoma 30.1 TP53 KRT7 ESR1 CEACAM5 CDX2 CDKN2A
40 oligodendroglioma 30.1 TP53 PTEN EGFR CDKN2A
41 papillary carcinoma 30.1 KRT7 KRT20 ESR1 CALB2
42 endometrial adenocarcinoma 30.1 TP53 PTEN KRT7 ESR1 EGFR CDKN2A
43 endometrial hyperplasia 30.1 TP53 PTEN ESR1
44 papilloma 30.1 TP53 RASSF1 PTEN KRT7 KRT20 ESR1
45 uterine carcinosarcoma 30.0 TP53 PTEN ESR1 EGFR CDKN2A
46 lynch syndrome 30.0 TP53 PTEN EGFR CDKN2A
47 rhabdomyosarcoma 30.0 TP53 PTEN EGFR CDKN2A CDKN1A
48 ovary adenocarcinoma 29.7 TP53 PTEN KRT7 KRT20 ESR1 EGFR
49 peritoneum cancer 29.7 TP53 PTEN KRT7 EGFR CEACAM5 CDKN2A
50 carcinosarcoma 29.7 TP53 PTEN KRT7 EGFR CEACAM5 CDKN2A

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 CDKN1A CDKN2A CDX2 CXCL12 EGFR ESR1
2 cardiovascular system MP:0005385 10.21 CDKN1A CDKN2A CDX2 CXCL12 EGFR ESR1
3 digestive/alimentary MP:0005381 10.18 CDKN1A CDKN2A CDX2 EGFR ESR1 LAMC2
4 immune system MP:0005387 10.14 CDKN1A CDKN2A CXCL12 EBAG9 EGFR ESR1
5 endocrine/exocrine gland MP:0005379 10.11 CDKN1A CDKN2A CDX2 EGFR ESR1 LRIG1
6 limbs/digits/tail MP:0005371 9.97 CDKN1A CDX2 EGFR ESR1 LAMC2 LRIG1
7 liver/biliary system MP:0005370 9.92 CDKN1A CDKN2A CXCL12 EGFR ESR1 PTEN
8 hearing/vestibular/ear MP:0005377 9.91 CDKN1A EGFR LAMC2 LRIG1 LRIG3 TP53
9 neoplasm MP:0002006 9.91 CDKN1A CDKN2A CDX2 EGFR ESR1 LRIG1
10 no phenotypic analysis MP:0003012 9.76 CDKN1A CDKN2A CXCL12 EGFR ESR1 LRIG1
11 normal MP:0002873 9.61 CALB2 CDX2 CXCL12 EGFR ESR1 LRIG1
12 skeleton MP:0005390 9.32 CDKN1A CDKN2A CDX2 EGFR ESR1 LAMC2

Drugs & Therapeutics for Cervical Adenocarcinoma

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Epoetin alfa Phase 4 113427-24-0
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
7
leucovorin Approved Phase 3 58-05-9 6006 143
8
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
9
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
10
Ifosfamide Approved Phase 3 3778-73-2 3690
11
Vinblastine Approved Phase 3 865-21-4 241903 13342
12
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
13
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
14
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
15
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Tirapazamine Investigational Phase 3 27314-97-2
18 Alkylating Agents Phase 3
19 Anti-Infective Agents Phase 3
20 Angiogenesis Inhibitors Phase 3
21 Immunologic Factors Phase 3
22 Antiviral Agents Phase 3
23 Immunosuppressive Agents Phase 3
24 Antimetabolites Phase 3
25 Tubulin Modulators Phase 3
26 topoisomerase I inhibitors Phase 3
27 Antimitotic Agents Phase 3
28 Anti-Bacterial Agents Phase 3
29 Antibiotics, Antitubercular Phase 3
30 Immunoglobulins Phase 3
31 Antibodies Phase 3
32 Antibodies, Monoclonal Phase 3
33 Antineoplastic Agents, Immunological Phase 3
34 Mitogens Phase 3
35 Endothelial Growth Factors Phase 3
36 Immunoglobulins, Intravenous Phase 3
37 Immunoglobulin G Phase 3
38 Antirheumatic Agents Phase 3
39 Vitamin B Complex Phase 3
40 Folate Phase 3
41 Folic Acid Antagonists Phase 3
42
Isophosphamide mustard Phase 3 0
43 Dermatologic Agents Phase 3
44 Mitomycins Phase 3
45 Vitamin B9 Phase 3
46 Albumin-Bound Paclitaxel Phase 3
47 Vaccines Phase 3
48
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
49
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
50
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
2 Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer Unknown status NCT00039338 Phase 3 cisplatin
3 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
4 A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
5 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
6 A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
9 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
10 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Recruiting NCT01101451 Phase 3 Cisplatin
11 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
12 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
13 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Active, not recruiting NCT03998254 Phase 3 V503;Gardasil
14 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
15 An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
16 Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation Terminated NCT00054067 Phase 3 cisplatin
17 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
18 Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
19 Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
20 A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB Unknown status NCT01158248 Phase 2 cisplatin
21 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
22 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
23 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
24 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
25 Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
26 Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix Completed NCT00003017 Phase 2
27 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
28 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
29 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
30 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
31 A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer Completed NCT02880007 Phase 2 Cisplatin
32 Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
33 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
34 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
35 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
36 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
37 A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer Completed NCT00278304 Phase 2
38 A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
39 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
40 A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer Completed NCT00559377 Phase 2
41 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
42 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
43 A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Completed NCT01230996 Phase 1, Phase 2 Cisplatin
44 CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
45 A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00101192 Phase 2 cisplatin
46 A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
47 Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
48 Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III Completed NCT00957411 Phase 2 cisplatin
49 A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
50 A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

40
Cervix, Lymph Node, Testes, T Cells, Breast, Lung, Uterus

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 1580)
# Title Authors PMID Year
1
P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. 54 61
20524403 2010
2
Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. 61 54
18202755 2008
3
Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. 61 54
18156982 2008
4
The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. 54 61
17981616 2008
5
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. 61 54
17252195 2007
6
Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. 54 61
17354237 2007
7
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 61 54
17360030 2007
8
[Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma]. 61 54
17355795 2007
9
Immunohistochemistry as a diagnostic aid in cervical pathology. 54 61
17365826 2007
10
Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. 61 54
16290001 2006
11
Immunohistochemical characterization of endocervical papillary serous carcinoma. 54 61
16515605 2006
12
p16 expression in the female genital tract and its value in diagnosis. 61 54
16462152 2006
13
The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. 61 54
16343183 2005
14
Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. 61 54
15337561 2004
15
The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. 61 54
15297173 2004
16
P16 as a molecular biomarker of cervical adenocarcinoma. 54 61
15041997 2004
17
Correlation between MUC5AC expression and the prognosis of patients with adenocarcinoma of the uterine cervix. 61 54
14699032 2004
18
Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel. 61 54
14632574 2003
19
CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. 61 54
12877729 2003
20
Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. 54 61
11248419 2001
21
The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. 61 54
11104614 2000
22
Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. 54 61
11006578 2000
23
Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. 54 61
10202666 1999
24
Evaluation of immunostaining for MIB1 and nm23 products in uterine cervical adenocarcinoma. 61 54
9823779 1998
25
Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. 54 61
9635534 1998
26
Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. 61 54
9476065 1998
27
[Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer]. 54 61
9772433 1997
28
Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. 61 54
9314589 1997
29
Molecular characterization of adenocarcinoma of the cervix. 61 54
9038270 1997
30
What is a normal CA125 level? 54 61
8175027 1994
31
Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. 61 54
8319181 1993
32
Oestrogen receptor protein and mRNA in adenocarcinoma of the uterine cervix. 54 61
1457356 1992
33
Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. 61 54
2258083 1990
34
Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. 61 54
2317761 1990
35
Mucin leakage into the cervical stroma may increase lymph node metastasis in mucin-producing cervical adenocarcinomas. 61 54
2153042 1990
36
Molecular epidemiology of human papillomavirus 18 infections in Japanese Women. 61
32360473 2020
37
High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma. 61
32435885 2020
38
Retinoic acid receptor-beta prevents cisplatin-induced proximal tubular cell death. 61
32278009 2020
39
Aldolase A promotes epithelial-mesenchymal transition to increase malignant potentials of cervical adenocarcinoma. 61
32530543 2020
40
Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy. 61
32527042 2020
41
Invasive cervical adenocarcinoma arising from extension of recurrent vulval Paget's disease. 61
32532900 2020
42
Computational evaluation and in vitro validation of new Epidermal Growth Factor Receptor inhibitors. 61
32493189 2020
43
Selective Control of Cell Activity with Hydrophilic Polymer-Covered Cationic Nanoparticles. 61
32253822 2020
44
Proposal of a Two-Tier System in Grouping Adenocarcinoma of the Uterine Cervix. 61
32429283 2020
45
Analysis of Conization Results in Patients undergoing Hysterectomy for Uterine Adenocarcinoma. 61
32483807 2020
46
Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. 61
32474915 2020
47
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. 61
32447296 2020
48
A Deceptive Spread: Myoinvasion of Endometrial Carcinoma Imitating Adenoma Malignum. 61
31690149 2020
49
Base Induced Condensation of Malononitrile with Erlenmeyer Azlactones: An Unexpected Synthesis of Multi-Substituted Δ2 -Pyrrolines and Their Cytotoxicity. 61
32147970 2020
50
Transtubal Spread of a Superficially Invasive Cervical Adenocarcinoma to the Ovaries After 11 Years. 61
31033802 2020

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 TP53 PTEN ESR1 EGFR CDX2 CDKN2A
2 12.37 TP53 RASSF1 PTEN EGFR CDKN2A CDKN1A
3
Show member pathways
12.3 TP53 RASSF1 PTEN ESR1 EGFR CDKN2A
4
Show member pathways
12.29 TP53 PTEN CDKN2A CDKN1A
5 12.25 TP53 PTEN CDKN2A CDKN1A
6
Show member pathways
12.21 TP53 PTEN EGFR CDKN1A
7 12.2 TP53 ESR1 EGFR CDKN1A
8 12.05 TP53 PTEN CDKN2A CDKN1A
9 12.04 TP53 PTEN ESR1 EGFR
10 12 TP53 RASSF1 PTEN LAMC2 ESR1 EGFR
11 11.95 TP53 PTEN EGFR CDKN1A
12 11.87 TP53 PTEN CDKN2A CDKN1A
13
Show member pathways
11.83 LRIG1 ESR1 EGFR CXCL12
14 11.8 TP53 PTEN CDKN2A CDKN1A
15 11.77 PTEN EGFR CDKN1A
16 11.72 TP53 PTEN LAMC2 CDKN1A
17 11.7 TP53 PTEN EGFR CDKN2A CDKN1A
18 11.66 TP53 CDKN2A CDKN1A
19 11.63 TP53 PTEN EGFR
20 11.43 ESR1 EGFR CDKN1A
21 11.41 TP53 PTEN CDKN1A
22 11.38 TP53 EGFR CDKN2A CDKN1A
23 11.28 TP53 PTEN ESR1
24 11.22 TP53 RASSF1 EGFR CDKN2A CDKN1A
25
Show member pathways
10.95 TP53 CDKN2A CDKN1A
26 10.71 TP53 CDKN1A
27
Show member pathways
10.5 TP53 CDKN1A

GO Terms for Cervical Adenocarcinoma

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.96 TP53 PTEN EGFR CEACAM5 CDKN1A
2 apoptotic process GO:0006915 9.95 TP53 PTEN KRT20 EBAG9 CEACAM5 CDKN2A
3 protein stabilization GO:0050821 9.8 TP53 PTEN CDKN2A CDKN1A
4 cell cycle arrest GO:0007050 9.67 TP53 RASSF1 CDKN2A CDKN1A
5 positive regulation of fibroblast proliferation GO:0048146 9.63 ESR1 EGFR CDKN1A
6 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.58 PTEN MIR362 CDKN1A
7 response to arsenic-containing substance GO:0046685 9.55 PTEN CDKN1A
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 EGFR
9 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.52 TP53 ESR1
10 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.51 TP53 ESR1
11 Ras protein signal transduction GO:0007265 9.46 TP53 RASSF1 CDKN2A CDKN1A
12 signal transduction by p53 class mediator GO:0072331 9.43 TP53 CDKN1A
13 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.43 PTEN CDKN2A CDKN1A
14 otolith morphogenesis GO:0032474 9.32 LRIG3 LRIG1
15 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.26 PTEN MIR362 CDKN2A CDKN1A
16 replicative senescence GO:0090399 8.8 TP53 CDKN2A CDKN1A

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CDKN2A CDKN1A
2 protein kinase binding GO:0019901 9.1 TP53 PTEN ESR1 EGFR CDKN2A CDKN1A
3 nitric-oxide synthase regulator activity GO:0030235 8.96 ESR1 EGFR

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....